Multimodal Actions of S1P Receptor Modulators in Multiple Sclerosis

In this episode, Patricia Coyle, MD, FAAN, describes the development of S1P modulator receptors, their mechanism of action, potential side effects, and considerations for patient suitability, particularly in comparison to other treatment options like monoclonal antibodies.

In this episode, Patricia Coyle, MD, FAAN, provides in-depth insight on fingolimod, the first approved S1P receptor modulator, and the clinical data pre- and post-approval.

In this episode, Adnan Subei, DO, FAAN, discusses siponimod, a selective S1P receptor modulator approved in 2019, its clinical advantages, efficacy, and how it may be useful for patients with multiple sclerosis.

Neurologist Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.

In this episode, Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.

In this episode, Patricia Coyle, MD, FAAN, gave clinical insight on some of the next steps regarding S1P-modulating therapies, including some of the advantages of newer generation agents and the need for future studies to investigate benefits and limitations to each.